What's on this Page
What is Tildrakizumab
Tildrakizumab is an interleukin-23 antagonist indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
The drug should only be given subcutaneously by a qualified health professional.
Prior to administration, all potential drug recipients must be evaluated for tuberculosis (TB) infections. DO NOT administer tildrakizumab to patients with active TB infection; patients with latent TB should initiate treatment before receiving tildrakizumab.
Brand Name
ILUMYA
Indications
- psoriasis
For the treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy
Side Effects
- angioedema
- antibody formation
- bleeding
- diarrhea
- edema
- erythema
- hematoma
- infection
- injection site reaction
- pharyngitis
- pruritus
- urticaria
Monitoring Parameters
- tuberculin skin test
Contraindications
- breast-feeding
- immunosuppression
- infection
- pregnancy
- tuberculosis
- vaccination
Interactions
- Bacillus Calmette-Guerin Vaccine, BCG
- Canakinumab
- Influenza Virus Vaccine
- Intranasal Influenza Vaccine
- Live Vaccines
- Measles Virus; Mumps Virus; Rubella Virus; Varicella Virus Vaccine, Live
- Measles/Mumps/Rubella Vaccines, MMR
- Rotavirus Vaccine
- Rubella Virus Vaccine Live
- Smallpox and Monkeypox Vaccine, Live, Nonreplicating
- Smallpox Vaccine, Vaccinia Vaccine
- Typhoid Vaccine
- Varicella-Zoster Virus Vaccine, Live
- Yellow Fever Vaccine, Live
